648904-84-1

Basic information

• Product Name: 4-Bromo-2-fluoro-1-(methylsulfonyl)benzene
• Synonyms: 4-Bromo-2-fluoro-1-(methylsulfonyl)benzene;4-Bromo-2-fluorophenyl methyl sulphone 98%;4-Bromo-2-fluoro-1-(methylsulphonyl)benzene;4-Bromo-2-fluorophenylmethylsulphone98%
• CAS NO: 648904-84-1
• Molecular Formula: C₇H₆BrFO₂S
• Molecular Weight: 253.09
• Mol File: 648904-84-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 344.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.669±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Bromo-2-fluoro-1-(methylsulfonyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-2-fluoro-1-(methylsulfonyl)benzene(648904-84-1)
• EPA Substance Registry System: 4-Bromo-2-fluoro-1-(methylsulfonyl)benzene(648904-84-1)

Safety Data

• Hazardous Substances Data: 648904-84-1(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-fluoro-1-(methylsulfonyl)benzene is a fluoro-substituted benzene compound that contains a bromine atom and a methylsulfonyl group. It is commonly used in organic synthesis as a reagent for the introduction of a fluoro substituent on various organic molecules. 4-Bromo-2-fluoro-1-(methylsulfonyl)benzene has been investigated for its potential applications in pharmaceuticals and agrochemicals due to its unique properties. Additionally, it is also used in the production of various industrial chemicals and materials. Overall, 4-Bromo-2-fluoro-1-(methylsulfonyl)benzene is a versatile chemical with diverse applications in both research and industrial settings.

Upstream product

• 221030-79-1 4-bromo-2-fluoro-1-methylsulfanylbenzene 
• 20277-69-4 sodium methansulfinate 
• 105931-73-5 1-bromo-3-fluoro-4-iodobenzene 
• 252561-34-5 3-fluoro-4-(methylsulfonyl)benzenamine 
• 656-65-5 3-fluoro-4-bromophenylamine 
• 174414-93-8 4-bromo-2-fluorobenzenethiol 

Downstream Products

• 731018-32-9 (E)-3-cyclohexyl-2-(3-fluoro-4-methanesulfonyl-phenyl)-prop-2-en-1-ol 
• 648906-23-4 4-bromo-1-methanesulfonyl-2-methylsulfanyl-benzene 
• 648904-85-2 2-(3-fluoro-4-methanesulfonyl-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane 
• 1314883-32-3 5-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(2-methoxypyridin-5-yl)pyridin-2-amine 
• 1104450-29-4 1-(3-fluoro-4-(methylsulfonyl)phenyl)-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-2(1H)-one 
• 400610-51-7 5-bromo-2-methanesulfonyl-phenylamine 
• 1415819-92-9 1-bromo-5-fluoro-4-(methylsulfonyl)-2-nitrobenzene 

Relevant articles and documents

JNK INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF

Provided are a compound shown in formula (I) below, and racemates, stereoisomers, tautomers, isotopic markers, solvates, polymorphs and oxynitrides of the compound, or a pharmaceutically acceptable salt thereof, wherein same can be used as JNK inhibitors. Also provided are a method for preparing the compound shown in formula (I), a pharmaceutical composition comprising the compound shown in formula (I), and the use of the compound shown in formula (I) for preparing drugs, wherein the drugs are used for treating diseases which can be treated by inhibiting JNK activity.

Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1 H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119

G-protein-coupled receptor 119 (GPR119) is expressed predominantly in pancreatic β-cells and in enteroendocrine cells in the gastrointestinal tract. GPR119 agonists have been shown to stimulate glucose-dependent insulin release by direct action in the pancreas and to promote secretion of the incretin GLP-1 by action in the gastrointestinal tract. This dual mechanism of action has generated significant interest in the discovery of small molecule GPR119 agonists as a potential new treatment for type 2 diabetes. Herein, we describe the discovery and optimization of a new class of pyridone containing GPR119 agonists. The potent and selective BMS-903452 (42) was efficacious in both acute and chronic in vivo rodent models of diabetes. Dosing of 42 in a single ascending dose study in normal healthy humans showed a dose dependent increase in exposure and a trend toward increased total GLP-1 plasma levels.

QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES

The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R6 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases